Regeneron Pharmaceuticals (REGN) Interest Expenses (2009 - 2026)

Regeneron Pharmaceuticals has reported Interest Expenses for 17 years, with the latest figure at $12.9 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 48.28% year-over-year to $12.9 million; the trailing twelve-month figure through Mar 2026 stood at $48.0 million (changed 0.42% YoY), and the FY2025 full-year result was $43.8 million, down 20.65% from the prior year.
• Interest Expenses for Q1 2026 stood at $12.9 million, up from $12.2 million in the prior quarter.
• The five-year high for Interest Expenses was $19.3 million in Q3 2025, with the low at $3.6 million in Q2 2025.
• Average Interest Expenses over 5 years is $14.4 million, with a median of $14.8 million recorded in 2024.
• Year-over-year, Interest Expenses slumped 75.68% in 2025 and soared 48.28% in 2026.
• Tracing REGN's Interest Expenses over 5 years: stood at $17.4 million in 2022, then increased by 5.17% to $18.3 million in 2023, then sank by 42.62% to $10.5 million in 2024, then gained by 16.19% to $12.2 million in 2025, then increased by 5.74% to $12.9 million in 2026.
• The last three Interest Expenses figures came in at $12.9 million (Q1 2026), $12.2 million (Q4 2025), and $19.3 million (Q3 2025), per Business Quant data.

Peer Comparison